September 30, 2023

A brand new editorial paper was printed in Oncoscience (Quantity 10) on August 17, 2023, entitled, “Most cancers drug growth yesterday, as we speak and tomorrow.” On this new editorial, researchers Elzbieta Izbicka and Robert T. Streeper from New Frontier Labs focus on the historical past of most cancers drug growth and the way it has advanced over time. The editorial additionally highlights the present state of most cancers drug growth and what the longer term could maintain.

Editorial Introduction:

The “battle on most cancers” started with the Nationwide Most cancers Act, a United States federal regulation meant “to amend the Public Well being Service Act in order to strengthen the Nationwide Most cancers Institute as a way to extra successfully perform the nationwide effort in opposition to most cancers” that was signed by President Richard Nixon on December 23, 1971. Because the fiftieth anniversary is now two years gone, the battle has not been essentially a blitzkrieg. To paraphrase Charles Dickens, as we speak “it’s the better of instances, it’s the worst of instances” for most cancers medication. Nice progress in most cancers remedy has been made because of the mixed influence of higher supportive care, ever bettering medication and earlier most cancers detection.

“However, the Anthropocene period brings new challenges as a result of elevated human influence of environmental elements, which together with modifications in food plan and way of life could contribute to a worrisome enhance in early-onset cancers, a scenario seen as a possible rising international epidemic.”


Journal reference:

Izbicka, E. & Streeper, R. T., (2023) Most cancers drug growth yesterday, as we speak and tomorrow. Oncoscience.